Literature DB >> 30411867

Role of induction chemotherapy in sinonasal malignancies: a systematic review.

Tawfiq Khoury1, David Jang1, Ricardo Carrau2, Neal Ready3, Ian Barak4, Ralph Abi Hachem1.   

Abstract

BACKGROUND: Cancers of the paranasal sinuses are rare tumors that tend to be aggressive and usually are diagnosed at an advanced stage. Despite being rare, these tumors include a wide spectrum of histological subtypes with different biological behaviors. Choosing the optimal treatment modalities and analyzing the different oncological outcomes is therefore challenging. This study aims to evaluate the role of induction chemotherapy prior to definitive local therapy for sinonasal malignancies.
METHODS: A systematic review of the literature in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted. With the assistance of a medical librarian, data sources including MEDLINE, PubMed, Cochrane library, EMBASE, NCBI Bookshelf, National Guideline Clearinghouse, and Clinicaltrials.gov were searched using a customized search strategy that yielded 1758 articles. Inclusion criteria used were as follows: (1) the study has a patient population with 3 or more patients with previously untreated sinonasal malignancies; (2) patients underwent induction chemotherapy prior to definitive local therapy; (3) pretreatment staging information was documented; (4) overall survival was reported by histology type either in table or Kaplan-Meier format. Nine studies with 220 patients ultimately met inclusion criteria and were analyzed in groups based on tumor histology.
RESULTS: For squamous cell carcinoma (SCC), the 5-year overall survival was 51%. For neuroendocrine tumors, the 5-year overall survival was 78%. Eighteen percent (18%) of patients with pretreatment orbital involvement ultimately underwent orbital exenteration.
CONCLUSION: Induction chemotherapy in the management of sinonasal malignancies has similar overall survival outcomes as other standard treatment modalities and can be offered as an option to patients as part of multimodality therapy.
© 2018 ARS-AAOA, LLC.

Entities:  

Keywords:  esthesioneuroblastoma; neoadjuvant chemotherapy; orbital/ocular; skull base; therapeutics

Mesh:

Year:  2018        PMID: 30411867     DOI: 10.1002/alr.22229

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  1 in total

Review 1.  Emerging concepts in sinonasal tumor research.

Authors:  Diana C Lopez; Andrew E Wadley; Nyall R London
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2022-02-01       Impact factor: 1.814

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.